Recently Featured

FDA Expands Vertex’s Casgevy Label to Include Patients as Young as 2

August 12, 2026
Vertex Pharmaceuticals has received FDA approval for a label expansion of its gene therapy Casgevy, now permitting treatment for children aged 2 and older suffering from sickle cell disease or transfusion-dependent beta thalassemia. Previously, the therapy was only available to patients aged 12 and above, marking a significant shift in treatment accessibility. This expansion reflects…

Sofinnova reports Myricx Bio to be acquired by Novartis

August 12, 2026
Novartis has announced its acquisition of Myricx Bio, a strategic move that aims to enhance its oncology portfolio through Myricx’s innovative antibody-drug conjugate (ADC) platform. This acquisition underscores Novartis’s commitment to advancing cancer treatment options and leveraging cutting-edge technologies to improve patient outcomes. The integration of Myricx Bio’s next-generation ADC capabilities into Novartis’s existing oncology…

Novartis to acquire Myricx Bio in up to $1.5bn deal

August 12, 2026
Novartis has signed an agreement to purchase Myricx Bio, a UK-based biotechnology company, in a transaction valued at up to $1.5 billion. This acquisition reflects Novartis’ strategic focus on enhancing its pipeline in innovative therapies, particularly in the realm of biologics and advanced therapeutics. The move comes as the pharmaceutical industry continues to see a…

MHRA Approves Retifanlimab (ZYNYZ) for Advanced Merkel Cell Skin Cancer Treatment

August 12, 2026
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for Retifanlimab, marketed as ZYNYZ, for the treatment of advanced Merkel cell carcinoma (MCC). This decision marks a significant advancement in the therapeutic options available for a rare and aggressive skin cancer that originates from Merkel cells, which are specialized neuroendocrine cells located…

Ongoing Cases